Yi Liu
Research Subjects
Research Interests
Yi Liu has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Amy D. Brideau-Andersen
Allergan Aesthetics, an AbbVie Company, Irvine, CA 92612, USA
1 shared publication - Andrew C. Chu
University of California Irvine
1 shared publication - Birgitte P.S. Jacky
Allergan Aesthetics, an AbbVie company
1 shared publication - David Rupp
Allergan Aesthetics, an AbbVie Company, Irvine, CA, USA
1 shared publication - Edwin Vazquez-Cintron
United States Army Medical Research Institute of Chemical Defense, Aberdeen Proving Ground, MD 21010, USA
1 shared publication - Gabriela S. Salcedo
Department of Chemistry, University of California Irvine, Irvine, California, USA
1 shared publication
Latest Publications
- Open Access
Reengineering the Specificity of the Highly Selective Clostridium botulinum Protease via Directed Evolution
The botulinum neurotoxin serotype A (BoNT/A) cuts a single peptide bond in SNAP25, an activity used to treat a wide range of diseases. Reengineering the substrate specificity of BoNT/A’s protease domain (LC/A) could expand its therapeutic applications; however, LC/A’s extended substrate recognition (≈60 residues) challenges conventional approaches. We report a directed evolution method for retargeting LC/A’s substrate and retaining its exquisite specificity. The resultant eight-mutation LC/A (omLC/A) has improved cleavage specificity and catalytic efficiency (1300- and 120-fold, respectively) for SNAP23 versus SNAP25 compared to a previously reported LC/A variant. Importantly, the BoNT/A holotoxin equipped with omLC/A infiltrates neurons and retains its SNAP23 activity. The identification of substrate control loops outside BoNT/A’s active site could guide the design of improved BoNT proteases and inhibitors. One Sentence Summary: Directed evolution of the BoNT/A protease targets a new cellular protein, SNAP23, expanding its therapeutic potential.
Open AccessReengineering the Specificity of the Highly Selective Clostridium botulinum Protease via Directed Evolution
The botulinum neurotoxin serotype A (BoNT/A) cuts a single peptide bond in SNAP25, an activity used to treat a wide range of diseases. Reengineering the substrate specificity of BoNT/A’s protease domain (LC/A) could expand its therapeutic applications; however, LC/A’s extended substrate recognition (≈60 residues) challenges conventional approaches. We report a directed evolution method for retargeting LC/A’s substrate and retaining its exquisite specificity. The resultant eight-mutation LC/A (omLC/A) has improved cleavage specificity and catalytic efficiency (1300- and 120-fold, respectively) for SNAP23 versus SNAP25 compared to a previously reported LC/A variant. Importantly, the BoNT/A holotoxin equipped with omLC/A infiltrates neurons and retains its SNAP23 activity. The identification of substrate control loops outside BoNT/A’s active site could guide the design of improved BoNT proteases and inhibitors. One Sentence Summary: Directed evolution of the BoNT/A protease targets a new cellular protein, SNAP23, expanding its therapeutic potential.